Cardiovascular disease management in people with diabetes outside North America and Western Europe in 2006 and 2015
- Autores
- Tabesh, Maryam; Magliano, D. J.; Tanamas, S. K.; Surmont, F.; Bahendeka, S.; Chiang, C. E.; Elgart, Jorge Federico; Gagliardino, Juan Jose; Kalra, Sanjay; Krishnamoorthy, S.; Luk, Andrea; Maegawa, H.; Motala, A. A.; Pirie, F.; Ramachandran, A.; Tayeb, K.; Vikulova, O.; Wong, J.; Shaw, J. E.
- Año de publicación
- 2019
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Aim: Optimal treatment of cardiovascular disease is essential to decrease mortality among people with diabetes, but information is limited on how actual treatment relates to guidelines. We analysed changes in therapeutic approaches to anti-hypertensive and lipid-lowering medications in people with Type 2 diabetes from 2006 and 2015. Methods: Summary data from clinical services in seven countries outside North America and Western Europe were collected for 39 684 people. Each site summarized individual-level data from outpatient medical records for 2006 and 2015. Data included: demographic information, blood pressure (BP), total cholesterol levels and percentage of people taking statins, anti-hypertensive medication (angiotensin-converting enzyme inhibitors, calcium channel blockers, angiotensin II receptor blockers, thiazide diuretics) and antiplatelet drugs. Results: From 2006 to 2015, mean cholesterol levels decreased in six of eight sites (range: −0.5 to −0.2), whereas the proportion with BP levels > 140/90 mmHg increased in seven of eight sites. Decreases in cholesterol paralleled increases in statin use (range: 3.1 to 47.0 percentage points). Overall, utilization of anti-hypertensive medication did not change. However, there was an increase in the use of angiotensin II receptor blockers and a decrease in angiotensin-converting enzyme inhibitors. The percentage of individuals receiving calcium channel blockers and aspirin remained unchanged. Conclusions: Our findings indicate that control of cholesterol levels improved and coincided with increased use of statins. The percentage of people with BP > 140/90 mmHg was higher in 2015 than in 2006. Hypertension treatment shifted from using angiotensin-converting enzyme inhibitors to angiotensin II receptor blockers. Despite the potentially greater tolerability of angiotensin II receptor blockers, there was no associated improvement in BP levels.
Fil: Tabesh, M.. Monash University; Australia
Fil: Magliano, D.J.. Baker Heart And Diabetes Institute; Australia
Fil: Tanamas, S.K.. Baker Heart And Diabetes Institute; Australia
Fil: Surmont, F.. Monash University; Australia
Fil: Bahendeka, S.. Baker Heart And Diabetes Institute; Australia
Fil: Chiang, C.-E.. Astrazeneca;
Fil: ELGART, JORGE FEDERICO. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico La Plata. Centro de Endocrinología Experimental y Aplicada (i); Argentina
Fil: Gagliardino, Juan Jose. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico La Plata. Centro de Endocrinología Experimental y Aplicada (i); Argentina
Fil: Kalra, S.. Centro de Endocrinología Experimental y Aplicada (conicet- Universidad Nacional de la Plata); Argentina
Fil: Krishnamoorthy, S.. Centro de Endocrinología Experimental y Aplicada (conicet- Universidad Nacional de la Plata); Argentina
Fil: Luk, A.. Bharti Hospital; India
Fil: Maegawa, H.. Dr. A Ramachandran's Diabetes Hospitals; India
Fil: Motala, A.A.. Prince Of Wales Hospital Hong Kong; Hong Kong
Fil: Pirie, F.. Shiga University Of Medical Science;
Fil: Ramachandran, A.. University Of Kwazulu-natal;
Fil: Tayeb, K.. University Of Kwazulu-natal;
Fil: Vikulova, O.. Dr. A Ramachandran's Diabetes Hospitals; India
Fil: Wong, J.. Al Noor Specialist Hospital;
Fil: Shaw, J.E.. Endocrinology Research Centre; - Materia
-
cardiovascular
diabetes
North America
Western Europe - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/94950
Ver los metadatos del registro completo
id |
CONICETDig_e0d6442899f72144080f88cf2f0ff8b9 |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/94950 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
Cardiovascular disease management in people with diabetes outside North America and Western Europe in 2006 and 2015Tabesh, MaryamMagliano, D. J.Tanamas, S. K.Surmont, F.Bahendeka, S.Chiang, C. E.Elgart, Jorge FedericoGagliardino, Juan JoseKalra, SanjayKrishnamoorthy, S.Luk, AndreaMaegawa, H.Motala, A. A.Pirie, F.Ramachandran, A.Tayeb, K.Vikulova, O.Wong, J.Shaw, J. E.cardiovasculardiabetesNorth AmericaWestern Europehttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3Aim: Optimal treatment of cardiovascular disease is essential to decrease mortality among people with diabetes, but information is limited on how actual treatment relates to guidelines. We analysed changes in therapeutic approaches to anti-hypertensive and lipid-lowering medications in people with Type 2 diabetes from 2006 and 2015. Methods: Summary data from clinical services in seven countries outside North America and Western Europe were collected for 39 684 people. Each site summarized individual-level data from outpatient medical records for 2006 and 2015. Data included: demographic information, blood pressure (BP), total cholesterol levels and percentage of people taking statins, anti-hypertensive medication (angiotensin-converting enzyme inhibitors, calcium channel blockers, angiotensin II receptor blockers, thiazide diuretics) and antiplatelet drugs. Results: From 2006 to 2015, mean cholesterol levels decreased in six of eight sites (range: −0.5 to −0.2), whereas the proportion with BP levels > 140/90 mmHg increased in seven of eight sites. Decreases in cholesterol paralleled increases in statin use (range: 3.1 to 47.0 percentage points). Overall, utilization of anti-hypertensive medication did not change. However, there was an increase in the use of angiotensin II receptor blockers and a decrease in angiotensin-converting enzyme inhibitors. The percentage of individuals receiving calcium channel blockers and aspirin remained unchanged. Conclusions: Our findings indicate that control of cholesterol levels improved and coincided with increased use of statins. The percentage of people with BP > 140/90 mmHg was higher in 2015 than in 2006. Hypertension treatment shifted from using angiotensin-converting enzyme inhibitors to angiotensin II receptor blockers. Despite the potentially greater tolerability of angiotensin II receptor blockers, there was no associated improvement in BP levels.Fil: Tabesh, M.. Monash University; AustraliaFil: Magliano, D.J.. Baker Heart And Diabetes Institute; AustraliaFil: Tanamas, S.K.. Baker Heart And Diabetes Institute; AustraliaFil: Surmont, F.. Monash University; AustraliaFil: Bahendeka, S.. Baker Heart And Diabetes Institute; AustraliaFil: Chiang, C.-E.. Astrazeneca;Fil: ELGART, JORGE FEDERICO. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico La Plata. Centro de Endocrinología Experimental y Aplicada (i); ArgentinaFil: Gagliardino, Juan Jose. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico La Plata. Centro de Endocrinología Experimental y Aplicada (i); ArgentinaFil: Kalra, S.. Centro de Endocrinología Experimental y Aplicada (conicet- Universidad Nacional de la Plata); ArgentinaFil: Krishnamoorthy, S.. Centro de Endocrinología Experimental y Aplicada (conicet- Universidad Nacional de la Plata); ArgentinaFil: Luk, A.. Bharti Hospital; IndiaFil: Maegawa, H.. Dr. A Ramachandran's Diabetes Hospitals; IndiaFil: Motala, A.A.. Prince Of Wales Hospital Hong Kong; Hong KongFil: Pirie, F.. Shiga University Of Medical Science;Fil: Ramachandran, A.. University Of Kwazulu-natal;Fil: Tayeb, K.. University Of Kwazulu-natal;Fil: Vikulova, O.. Dr. A Ramachandran's Diabetes Hospitals; IndiaFil: Wong, J.. Al Noor Specialist Hospital;Fil: Shaw, J.E.. Endocrinology Research Centre;Wiley Blackwell Publishing, Inc2019-07info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/94950Tabesh, Maryam; Magliano, D. J.; Tanamas, S. K.; Surmont, F.; Bahendeka, S.; et al.; Cardiovascular disease management in people with diabetes outside North America and Western Europe in 2006 and 2015; Wiley Blackwell Publishing, Inc; Diabetic Medicine; 36; 7; 7-2019; 878-8870742-3071CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.1111/dme.13858info:eu-repo/semantics/altIdentifier/url/https://onlinelibrary.wiley.com/doi/full/10.1111/dme.13858info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T10:45:08Zoai:ri.conicet.gov.ar:11336/94950instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 10:45:09.177CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
Cardiovascular disease management in people with diabetes outside North America and Western Europe in 2006 and 2015 |
title |
Cardiovascular disease management in people with diabetes outside North America and Western Europe in 2006 and 2015 |
spellingShingle |
Cardiovascular disease management in people with diabetes outside North America and Western Europe in 2006 and 2015 Tabesh, Maryam cardiovascular diabetes North America Western Europe |
title_short |
Cardiovascular disease management in people with diabetes outside North America and Western Europe in 2006 and 2015 |
title_full |
Cardiovascular disease management in people with diabetes outside North America and Western Europe in 2006 and 2015 |
title_fullStr |
Cardiovascular disease management in people with diabetes outside North America and Western Europe in 2006 and 2015 |
title_full_unstemmed |
Cardiovascular disease management in people with diabetes outside North America and Western Europe in 2006 and 2015 |
title_sort |
Cardiovascular disease management in people with diabetes outside North America and Western Europe in 2006 and 2015 |
dc.creator.none.fl_str_mv |
Tabesh, Maryam Magliano, D. J. Tanamas, S. K. Surmont, F. Bahendeka, S. Chiang, C. E. Elgart, Jorge Federico Gagliardino, Juan Jose Kalra, Sanjay Krishnamoorthy, S. Luk, Andrea Maegawa, H. Motala, A. A. Pirie, F. Ramachandran, A. Tayeb, K. Vikulova, O. Wong, J. Shaw, J. E. |
author |
Tabesh, Maryam |
author_facet |
Tabesh, Maryam Magliano, D. J. Tanamas, S. K. Surmont, F. Bahendeka, S. Chiang, C. E. Elgart, Jorge Federico Gagliardino, Juan Jose Kalra, Sanjay Krishnamoorthy, S. Luk, Andrea Maegawa, H. Motala, A. A. Pirie, F. Ramachandran, A. Tayeb, K. Vikulova, O. Wong, J. Shaw, J. E. |
author_role |
author |
author2 |
Magliano, D. J. Tanamas, S. K. Surmont, F. Bahendeka, S. Chiang, C. E. Elgart, Jorge Federico Gagliardino, Juan Jose Kalra, Sanjay Krishnamoorthy, S. Luk, Andrea Maegawa, H. Motala, A. A. Pirie, F. Ramachandran, A. Tayeb, K. Vikulova, O. Wong, J. Shaw, J. E. |
author2_role |
author author author author author author author author author author author author author author author author author author |
dc.subject.none.fl_str_mv |
cardiovascular diabetes North America Western Europe |
topic |
cardiovascular diabetes North America Western Europe |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/3.2 https://purl.org/becyt/ford/3 |
dc.description.none.fl_txt_mv |
Aim: Optimal treatment of cardiovascular disease is essential to decrease mortality among people with diabetes, but information is limited on how actual treatment relates to guidelines. We analysed changes in therapeutic approaches to anti-hypertensive and lipid-lowering medications in people with Type 2 diabetes from 2006 and 2015. Methods: Summary data from clinical services in seven countries outside North America and Western Europe were collected for 39 684 people. Each site summarized individual-level data from outpatient medical records for 2006 and 2015. Data included: demographic information, blood pressure (BP), total cholesterol levels and percentage of people taking statins, anti-hypertensive medication (angiotensin-converting enzyme inhibitors, calcium channel blockers, angiotensin II receptor blockers, thiazide diuretics) and antiplatelet drugs. Results: From 2006 to 2015, mean cholesterol levels decreased in six of eight sites (range: −0.5 to −0.2), whereas the proportion with BP levels > 140/90 mmHg increased in seven of eight sites. Decreases in cholesterol paralleled increases in statin use (range: 3.1 to 47.0 percentage points). Overall, utilization of anti-hypertensive medication did not change. However, there was an increase in the use of angiotensin II receptor blockers and a decrease in angiotensin-converting enzyme inhibitors. The percentage of individuals receiving calcium channel blockers and aspirin remained unchanged. Conclusions: Our findings indicate that control of cholesterol levels improved and coincided with increased use of statins. The percentage of people with BP > 140/90 mmHg was higher in 2015 than in 2006. Hypertension treatment shifted from using angiotensin-converting enzyme inhibitors to angiotensin II receptor blockers. Despite the potentially greater tolerability of angiotensin II receptor blockers, there was no associated improvement in BP levels. Fil: Tabesh, M.. Monash University; Australia Fil: Magliano, D.J.. Baker Heart And Diabetes Institute; Australia Fil: Tanamas, S.K.. Baker Heart And Diabetes Institute; Australia Fil: Surmont, F.. Monash University; Australia Fil: Bahendeka, S.. Baker Heart And Diabetes Institute; Australia Fil: Chiang, C.-E.. Astrazeneca; Fil: ELGART, JORGE FEDERICO. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico La Plata. Centro de Endocrinología Experimental y Aplicada (i); Argentina Fil: Gagliardino, Juan Jose. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico La Plata. Centro de Endocrinología Experimental y Aplicada (i); Argentina Fil: Kalra, S.. Centro de Endocrinología Experimental y Aplicada (conicet- Universidad Nacional de la Plata); Argentina Fil: Krishnamoorthy, S.. Centro de Endocrinología Experimental y Aplicada (conicet- Universidad Nacional de la Plata); Argentina Fil: Luk, A.. Bharti Hospital; India Fil: Maegawa, H.. Dr. A Ramachandran's Diabetes Hospitals; India Fil: Motala, A.A.. Prince Of Wales Hospital Hong Kong; Hong Kong Fil: Pirie, F.. Shiga University Of Medical Science; Fil: Ramachandran, A.. University Of Kwazulu-natal; Fil: Tayeb, K.. University Of Kwazulu-natal; Fil: Vikulova, O.. Dr. A Ramachandran's Diabetes Hospitals; India Fil: Wong, J.. Al Noor Specialist Hospital; Fil: Shaw, J.E.. Endocrinology Research Centre; |
description |
Aim: Optimal treatment of cardiovascular disease is essential to decrease mortality among people with diabetes, but information is limited on how actual treatment relates to guidelines. We analysed changes in therapeutic approaches to anti-hypertensive and lipid-lowering medications in people with Type 2 diabetes from 2006 and 2015. Methods: Summary data from clinical services in seven countries outside North America and Western Europe were collected for 39 684 people. Each site summarized individual-level data from outpatient medical records for 2006 and 2015. Data included: demographic information, blood pressure (BP), total cholesterol levels and percentage of people taking statins, anti-hypertensive medication (angiotensin-converting enzyme inhibitors, calcium channel blockers, angiotensin II receptor blockers, thiazide diuretics) and antiplatelet drugs. Results: From 2006 to 2015, mean cholesterol levels decreased in six of eight sites (range: −0.5 to −0.2), whereas the proportion with BP levels > 140/90 mmHg increased in seven of eight sites. Decreases in cholesterol paralleled increases in statin use (range: 3.1 to 47.0 percentage points). Overall, utilization of anti-hypertensive medication did not change. However, there was an increase in the use of angiotensin II receptor blockers and a decrease in angiotensin-converting enzyme inhibitors. The percentage of individuals receiving calcium channel blockers and aspirin remained unchanged. Conclusions: Our findings indicate that control of cholesterol levels improved and coincided with increased use of statins. The percentage of people with BP > 140/90 mmHg was higher in 2015 than in 2006. Hypertension treatment shifted from using angiotensin-converting enzyme inhibitors to angiotensin II receptor blockers. Despite the potentially greater tolerability of angiotensin II receptor blockers, there was no associated improvement in BP levels. |
publishDate |
2019 |
dc.date.none.fl_str_mv |
2019-07 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/94950 Tabesh, Maryam; Magliano, D. J.; Tanamas, S. K.; Surmont, F.; Bahendeka, S.; et al.; Cardiovascular disease management in people with diabetes outside North America and Western Europe in 2006 and 2015; Wiley Blackwell Publishing, Inc; Diabetic Medicine; 36; 7; 7-2019; 878-887 0742-3071 CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/94950 |
identifier_str_mv |
Tabesh, Maryam; Magliano, D. J.; Tanamas, S. K.; Surmont, F.; Bahendeka, S.; et al.; Cardiovascular disease management in people with diabetes outside North America and Western Europe in 2006 and 2015; Wiley Blackwell Publishing, Inc; Diabetic Medicine; 36; 7; 7-2019; 878-887 0742-3071 CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/doi/10.1111/dme.13858 info:eu-repo/semantics/altIdentifier/url/https://onlinelibrary.wiley.com/doi/full/10.1111/dme.13858 |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Wiley Blackwell Publishing, Inc |
publisher.none.fl_str_mv |
Wiley Blackwell Publishing, Inc |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1844614490273873920 |
score |
13.070432 |